October 24, 2017 / 1:15 PM / in a month

BRIEF-Sienna Biopharmaceuticals announces first patient dosed in phase 2B trial of topical SNA-120

Oct 24 (Reuters) - Sienna Biopharmaceuticals Inc

* Sienna Biopharmaceuticals announces first patient dosed in phase 2B trial of topical SNA-120

* Sienna Biopharmaceuticals Inc - ‍top-line results expected in first half of 2019​

* Sienna Biopharmaceuticals - ‍phase 2B trial of topical SNA-120 to enroll about 190 patients with Pruritus associated with psoriasis​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below